This technology includes a micro-engineered “thyroid-on-a-chip” that combines human thyroid organoids with integrated micro-vasculature to replicate the gland’s native blood flow and 3-D architecture, enabling rapid, patient-specific drug screening. By permitting real-time perfusion of nutrients, hormones, and immune cells, the platform yields more physiologically relevant data than conventional static cultures or animal surrogates. Its modular design accommodates cells from individual patients, helping clinicians predict therapeutic response and tailor treatment for thyroid cancers and autoimmune disorders. In pharmaceutical R&D, the chip shortens pre-clinical timelines by providing actionable efficacy and toxicity read-outs within days. Overall, the system offers a high-fidelity bridge between benchtop discovery and clinical decision-making, addressing an unmet need for robust human thyroid models.